Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: A population-based follow-up study

Scandinavian Journal of Urology

Volumn 49, Issue 4, 2015, Pages 290-295

  Liedberg, Fredrik ^a   Hagberg, Oskar ^b   Holmäng, Sten ^c   Hosseini Aliabad, Abolfazl ^d   Jancke, Georg ^e   Ljungberg, Börje ^f   Malmström, Per Uno ^g   Åberg, Hanna ^b   Jahnson, Staffan ^b,e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b South Swedish Regional   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; Non muscle invasive; Progression; Recurrence

Indexed keywords

BCG VACCINE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RECURRENCE RISK; SWEDEN; AGE; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; HOSPITAL; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; UROLOGIC SURGERY; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84937555640     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.3109/21681805.2014.1000963     Document Type: Article

References (18)

1. Kimeney LA. Geographical and temporal trends in bladder cancer occurrence. So what? Eur Urol 2014;66:74-5.
2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.
3. Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014;120:408-14.
4. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-41.
5. Skolarus TA, Ye Z, Zhang S, Hollenbeck BK. Regional differences in early stage bladder cancer care and outcomes. Urology 2010;76:391-6.
6. van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010;106:206-11.
7. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Gue-rin: results of a retrospective multicenter study of 2451 patients. Eur Urol 2015;67:74-82.
8. Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012;109:1666-73.
9. Jancke G, Rosell J, Jahnson S. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. Scand J Urol 2014;48:276-83.
10. Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. Urol Oncol 2012;30:81-8.
11. Grotenhuis AJ, Ebben CW, Aben KK, Witjes JA, Vrieling A, Vermeulen SH, et al. The effect of smoking and timing of smoking cessation on clinical outcome n non-muscle-invasive bladder cancer. Urol Oncol 2014. [Epub ahead of print].
12. Pawinski A, Sylvester R, Kurth K, Bouffioux C, van der Meijden A, Parmar M, et al. A combined analysis of european organisation for research and treatment of cancer and medical research council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996;156:1934-41.
13. Sylvester RJ, van der Meijden A, Lamm DL. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
14. Hedelin H, Holmäng S, Wiman L. The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 2002;36:344-7.
15. Svatek RS, Hollenbeck BK, Holmäng S, Lee R, Kim SP, Stenzl A, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014;66:253-62.
16. Bryan RT, Kirby R, O'Brien T, Mostafid H. So much cost, such little progress. Eur Urol 2014;66:263-4.
17. Mostafid H, Brausi M. Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int 2012;109:579-82.
18. Nationellt kvalitetsregister for urinblasecancer: Nationell kvalitetsrapport for diagnosar. 2012. Available from http://cancercentrum. se/Global/Diagnoser/blascancer/rapporter/arsrapport2012-blascancerregistret- mar14. pdf. [Last accessed 14 September 2014].